13th July 2026

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
1st Floor, New Trading Ring, Rotunda Building,
P.J. Towers, Dalal Street, Fort,
Mumbai – 400001

BSE Scrip Code: - 975354

ISIN (Debt) – INE0SYQ07015

Subject: Outcome of the Board Meeting held on 13th July 2026

Dear Sir/ Madam,

In continuation of our filing dated 8th July 2026 and pursuant to Regulations 51, 52 read with Part B of Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (referred to as the "SEBI Listing Regulations"), the Board of Directors of the Company, at its Meeting held today, i.e. Monday 13th July 2026, has inter alia, considered and approved the following:

- Un-audited Standalone Financial Results of the Company for the quarter ended 30th June 2026.
- Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June 2026.
- Appointment of M/s. Shome and Banerjee (Firm Registration No. 000001) as a Cost Auditor of the Company for the financial year 2026-27. Disclosures required under SEBI Listing Regulations, is provided in 'Annexure I'.
- Appointment of Mr. Charanjit Singh, as Internal Auditor of the Company for the financial year 2026-27. Disclosures required under SEBI Listing Regulations, is provided in 'Annexure II'.
- Appointment of M/s Prajot Tungare and Associates, Company Secretaries, as secretarial auditor to fill the casual vacancy caused by the resignation of Secretarial Auditor for the financial year 2025-26. Disclosures required under SEBI Listing Regulations, is provided in 'Annexure III'.
- Recommending the appointment of M/s Prajot Tungare and Associates, Company Secretaries, as secretarial auditor for the First term of four (4) consecutive years, for the financial year 2026-2027 to 2029-30, subject to approval of the shareholders at the forthcoming Annual General Meeting of the Company.

Further, a copy of the Un-audited Financial Results (Standalone and Consolidated) of the Company, for the quarter ended 30th June 2026 along with the Limited Review Report issued by the Statutory Auditors of the Company is enclosed herewith for your records.

A Certificate of Security Cover pursuant to Regulation 54 of the SEBI Listing Regulations is also enclosed.

The Meeting of the Board of Directors of the Company commenced at 5:00 P.M. and concluded at 7.00 P.M.

We request you to take the afore-mentioned information on record and oblige

Yours faithfully,
For Aquapharm Chemical Limited
(Formerly known as Advaya Chemical Industries Limited)

Jayesh Gopal Damle
Digitally signed by Jayesh Gopal Damle
Date: 2026.07.13 19:15:29 +05'30'

Jayesh Damle
Company Secretary and Compliance Officer
Membership No: ACS24869

Encl: As Above

Annexure I

Appointment of M/s. Shome and Banerjee (Firm Registration No. 000001) as a Cost Auditor of the Company for the financial year 2026-27.

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~	Appointment as Cost Auditor of the Company for the financial year 2026-27.
2.	Date of appointment ~~/ reappointment/ cessation~~ (as applicable) and term of appointment/~~reappointment~~	Monday, 13th July 2026.
3.	Term of appointment	The Cost Auditor is appointed for the financial year 2026-27.
4.	Brief profile (in case of appointment)	M/s Shome & Banerjee, Cost Accountants was established in 1968. It is the first partnership firm of cost accountants registered in India, with over 55 years of dedicated service. The headquarter of the firm is located in Kolkata, with branches in Mumbai and Delhi. The firm has seven partners and offers expert services in the area of cost audit, cost & management consultancy, internal audit, taxation and other assurance services. Backed by a team of seasoned professionals, it serves a wide range of clients across industries and geographies, including major corporates like Tata Steel, JSW Steel, Reliance industries, Schneider, NTPC, BHEL, SAIL, ONGC, Reliance Jio, CESC, PCBL, Berger Paints, Tata Consumer Products, Woodlands Hospital etc. The firm is known for its commitment to quality, integrity and value-added service.
5.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable.

Annexure II

Appointment of Mr. Charanjit Singh, as Internal Auditor of the Company for the financial year 2026-27.

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~	Appointment as Internal Auditor of the Company for the financial year 2026-27.
2.	Date of appointment ~~/ reappointment/ cessation~~ (as applicable) and term of appointment/~~reappointment~~	Monday, 13th July 2026.
3.	Term of appointment	The Internal Auditor is appointed for the financial year 2026-27.
4.	Brief profile (in case of appointment)	Mr. Charanjit is a Chartered Accountant and has gained more than 14 years of experience while working in top-tier consulting firms like EY & PwC and Jindal Steel & Power Limited (industry). He has been associated with the RPSG Group (Group Internal Audit) for more than 2 years now. He has expertise in the areas of internal audit, enterprise risk management, fraud risk assessment, complex and large-scale corporate investigations, setting-up ethics and compliance framework, forensic audits of non-performing asset/ corporate debtors and data analytics. Apart from a being a Chartered Accountant, he has also cleared all the three levels of Company Secretary examination conducted by The Institute of Company Secretaries of India (ICSI) and has earned a bachelor's degree in commerce from the University of Calcutta."
5.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable.

Annexure-III

Appointment of M/s Prajot Tungare and Associates, Company Secretaries, as secretarial auditor to fill the casual vacancy caused by the resignation of Secretarial Auditor for the financial year 2025-26.

Sr. No.	Particulars	Secretarial Auditor
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~	Appointment as Secretarial Auditor of the Company to fill the casual vacancy caused by the resignation of Secretarial Auditor
2.	Date of appointment/~~cessation (as applicable) & term of appointment~~	Monday, 13th July 2026.
3.	Term of appointment	Secretarial Auditor is appointed to fill the casual vacancy caused by the resignation of Secretarial Auditor. Accordingly, the Secretarial Auditor shall conduct the secretarial audit for the financial year 2025-26 and shall hold office until the conclusion of the next Annual General Meeting i.e. the upcoming Annual General Meeting to be held for the Financial Year 2025-26.
4.	Brief profile (in case of appointment);	M/s. Prajot Tungare & Associates was established in 2001 and has experience of more than two decades. M/s. Prajot Tungare & Associates is a peer reviewed certified firm in accordance with the relevant guidelines of The Institute of Company Secretaries of India and has experience in providing services of business set-up and closure, corporate governance, certification and attestations, due diligence, corporate secretarial services, scrutinizer services and securities law.
5.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Aquapharm Chemical Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Aquapharm Chemical Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 52 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

Sl. No.	Name of the Company	Relationship
1	Aquapharm Chemical Limited (ACL)	Holding Company
2.	Aquapharm Europe B.V.	Wholly owned Subsidiary of ACL
3.	Aquapharm Chemicals LLC (Aqua LLC)	Wholly owned Subsidiary of ACL
4.	Aquapharm PChem LLC	Wholly owned Subsidiary of Aqua LLC
5.	Aquapharm Speciality Chemicals LLC	Wholly owned Subsidiary of Aqua LLC
6.	Unique Solutions for Chemical Industries Co. (USCI)	Subsidiary of ACL
7.	USCI LLC	Wholly owned Subsidiary of USCI

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of three (3) subsidiaries, whose unaudited interim financial results include total revenues of Rs 55.36 crores, total net profit after tax of Rs. 2.33 crores and total comprehensive income of Rs. 2.16 crores, for the quarter ended June 30, 2026 as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries, is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm registration number: 301003E/E300005

JAI PRAKASH YADAV
Digitally signed by JAI PRAKASH YADAV
DN: cn=JAI PRAKASH YADAV, c=IN, o=Personal
Date: 2026.07.13 18:56:50 +05'30'

per Jai Prakash Yadav
Partner
Membership No.: 066943

UDIN: 26066943HQYHPF2822

Place: Mumbai
Date: July 13, 2026

RP - Sanjiv Goenka Group
Growing Legacies

AQUAPHARM

Aquapharm Chemical Limited (Formerly known as "Advaya Chemical Industries Limited")

Registered Office : 9th&10th Floor, "Amar Synergy", 12B, Sadhu Vaswani Road, Pune 411001, India. CIN : U20299PN2024PLC227198

Statement of Unaudited Consolidated Financial Results for the quarter ended 30th June 2026

Website : www.aquapharm-india.com, Phone No. : (+91) 20 6609 0000

(All amounts are in INR Crores, unless otherwise stated)

Particulars	Consolidated			
	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited (Refer note 3)	Unaudited	Audited
Revenue from Operations	393.83	338.54	382.53	1,442.73
Other Income	0.70	0.22	0.68	2.29
Total Income	**394.53**	**338.76**	**383.21**	**1,445.02**
Expenses				
Cost of raw materials consumed	273.76	194.76	241.76	866.77
Purchases of stock-in-trade	-	-	1.09	1.82
Changes in inventories of finished goods and work-in-progress	(33.41)	24.30	(1.48)	28.00
Employee benefits expense	42.28	39.57	38.30	159.79
Finance costs	25.25	25.04	27.32	106.47
Depreciation and amortisation expense	36.50	35.90	35.80	143.37
Other expenses	64.68	51.20	53.27	226.73
Total Expenses	**409.06**	**370.77**	**396.06**	**1,532.95**
Profit / (Loss) before tax and exceptional item	**(14.53)**	**(32.01)**	**(12.85)**	**(87.93)**
Exceptional item :				
Impact of new labour codes	-	3.87	-	11.54
Profit / (Loss) before tax	**(14.53)**	**(35.88)**	**(12.85)**	**(99.47)**
Tax expense/(credit)				
Current Tax	0.64	(3.50)	4.15	3.21
Deferred Tax	(4.54)	(8.56)	(8.08)	(31.21)
Tax credit relating to earlier years	-	-	(3.22)	(2.77)
Total tax expense/(credit)	**(3.90)**	**(12.06)**	**(7.15)**	**(30.77)**
Profit / (Loss) after tax	**(10.63)**	**(23.82)**	**(5.70)**	**(68.70)**
Other Comprehensive Income / (Loss) (OCI)				
Items that will not be reclassified to profit or loss				
Remeasurements of post employment defined benefit plans	-	0.47	-	0.34
Income tax relating to items that will not be reclassified to Profit or Loss	-	(0.12)	-	(0.09)
Total (A)	**-**	**0.35**	**-**	**0.25**
Items that will be reclassified to profit or loss				
Exchange differences on translation of foreign operations	(0.42)	18.28	0.47	35.92
Total (B)	**(0.42)**	**18.28**	**0.47**	**35.92**
Other Comprehensive Income / (Loss) for the period, net (A+B)	**(0.42)**	**18.63**	**0.47**	**36.17**
Total Comprehensive Income / (Loss)	**(11.05)**	**(5.19)**	**(5.23)**	**(32.53)**
Profit/(Loss) attributable to :				
Owners of the equity	(10.67)	(23.71)	(5.64)	(68.50)
Non-controlling interest	0.04	(0.11)	(0.06)	(0.20)
Other Comprehensive Income/(Loss) attributable to :				
Owners of the equity	(0.42)	18.75	0.47	36.40
Non-controlling interest	0.00	(0.12)	0.00	(0.23)
Total Comprehensive Income/(Loss) attributable to :				
Owners of the equity	(11.09)	(4.96)	(5.17)	(32.10)
Non-controlling interest	0.04	(0.23)	(0.06)	(0.43)
Paid-up Equity Share Capital (Face value of INR 10/- each)	2,850.00	2,850.00	2,850.00	2,850.00
Other Equity				(87.44)
Earnings / (Loss) per equity share (EPS) (INR)				
(Nominal value per share INR 10/-)				
Basic and diluted*	(0.04)	(0.08)	(0.02)	(0.24)
(* not annualised except for year end)				

RP - Sanjiv Goenka Group Growing Legacies

AQUAPHARM

1. Additional information as per Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The Company has issued 55,000 rated, listed, secured, redeemable, non-convertible debentures of face value of INR 1,00,000 each, aggregating to INR 550 crore, subscribed by DBS Bank Limited, (referred to as the "Debentures") in the FY 23-24. 15% of the issue amount i.e. INR 82.50 crores have been repaid on 29th January 2025, 15% of the issue amount i.e. INR 82.50 crores have been repaid on 29th January 2026 and INR 385 crores is outstanding as on 30th June 2026 and accordingly the following disclosures are being made as per Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Particulars	Consolidated			
	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited (Refer note 3)	Unaudited	Audited
Debt Equity Ratio	0.45	0.42	0.41	0.42
Debt Service Coverage Ratio	0.34	0.19	1.70	0.58
Interest Service Coverage Ratio	0.29	(0.60)	0.39	(0.05)
Net Worth (INR Crore)	2,751.46	2,762.56	2,789.51	2,762.56
Net Profit after tax (INR Crore)	(10.63)	(23.82)	(5.70)	(68.70)
Earnings/(Loss) per share (Basic and Diluted) *	(0.04)	(0.08)	(0.02)	(0.24)
Current Ratio	0.97	0.89	1.04	0.89
Long Term Debt to Working Capital Ratio	5.53	9.73	4.81	9.73
Bad Debts to Account receivable Ratio	-	-	-	0.01
Current Liability Ratio	0.51	0.50	0.47	0.50
Total Debts to Total Assets Ratio	0.28	0.27	0.26	0.27
Debtor Turnover-Days	74.16	80.48	69.92	76.58
Inventory Turnover-Days	85.06	62.38	81.54	59.36
Operating Margin (%)	10.33%	6.83%	11.05%	9.24%
Net Profit Margin (%)	(2.70%)	(7.04%)	(1.49%)	(4.76%)

* not annualised except for year end

The debentures subscribed by DBS Bank Limited for INR 550 crore, are secured by way of 1st ranking pari-paasu charge on all movable fixed and current assets, negative lien on immovable properties of the Company, Hypothecation on investments/loans and advances made in foreign subsidiaries by the Company and Non-Disposal Undertaking on equity shares of the foreign subsidiaries to the lenders of the Company to the extent of the security cover of 1x in terms of the Deed of Hypothecation dated 20th March 2025 executed with the debenture trustee.

There is no deviation or variation in the use of proceeds of issue of the Debentures from the objects stated in the Information Memorandum.

The Company does not have any Outstanding redeemable preference shares as on 30th June 2026.
There is no requirement of creation of capital redemption reserve/ debenture redemption reserve as per the Companies Act, 2013.
As on 30th June 2026, the Company had no outstanding listed commercial papers.

Formulas for computation of above ratios are as follows:

Debt Equity Ratio= (Non Current Borrowings + Current Borrowings) / Total Equity

Debt Service Coverage Ratio= (Net profit/(loss) after tax+ Depreciation and amortisation expense + Finance costs excluding interest on lease liabilities+net loss/(gain) on foreign currency transaction+loss/(gain) on disposal of property,plant and equipment) /Debt Service (Interest+ Principal Loan repayment).

Interest Service Coverage Ratio= EBIT (Profit/(loss) Before Tax + Finance Costs)/Finance Costs
(Finance Costs = Interest expenses on debts and borrowings + Other borrowing costs + net loss/(gain) on foreign currency transaction/translation - interest on Lease rent)

Net worth means the aggregate of Equity Share Capital and Other Equity; Other Equity includes retained earnings and foreign currency translation reserve.

Current Ratio = Total Current Assets / Total Current Liabilities

Long term Debt to Working Capital = Non current borrowings including current maturities of long-term debt/ (Current Assets- Current Liabilities excluding current maturities of long term debt)

Bad Debt to Accounts Receivable ratio= Bad Debt (incl Provision for Bad Debts) / Trade Receivables

Current Liabilty Ratio= Total Current Liabilities / Total Liabilities

Total Debts to Total Assets= (Non Current Borrowings+ Current Borrowings) / Total Assets

Debtors Turnover Ratio Days = Sales(Sales of Finished Goods and Traded Goods) / Trade Receivables

Inventory Turnover= Sales(Sales of Finished Goods and Traded Goods)/ Inventories (Raw Materials + Semi Finished Goods +Finished Goods + Stores and spares parts (including packing material).

Operating Margin (%)= (Operating Profit/(loss) (Profit Before Tax +Depreciation and amortisation expenses+Finance Costs-Payment of Lease Liability+Net loss / (gain) on foreign currency transaction+Loss/ (gain) on disposal of property, plant and equipment - Other Income) / Revenue from Operations.

Net Profit Margin(%) = Net profit/(loss) after tax / Revenue from Operations

Notes to the Unaudited Consolidated Financial Results

2 The above unaudited consolidated financial results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on 13th July 2026. These unaudited consolidated financial results have been subjected to limited review by the statutory auditors of the Company in accordance with Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("the Regulations") and who have issued an unmodified conclusion on these unaudited consolidated financial results.

3 The figures for the quarter ended 31st March, 2026 are the balancing figures in respect of full financial year upto 31st March, 2026 and unaudited published year-to-date figures upto 31st December, 2025 being the date of the end of the third quarter of the financial year which were subject to a limited review.

4 The Company has only one business segment, i.e. chemical and does not operate in any other reportable segment as per Ind AS 108 : Operating segments.

For and on behalf of Board of Directors of Aquapharm Chemical Limited
(Formerly known as "Advaya Chemical Industries Limited")

Ganesh Vishwanathan
Digitally signed by Ganesh Vishwanathan
Date: 2026.07.13 18:29:55 +05'30'

Ganesh Vishwanathan
Whole-time Director and Chief Financial Officer
(DIN: 11259872)

Pune
13th July 2026

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India

Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Aquapharm Chemical Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Aquapharm Chemical Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm registration number: 301003E/E300005

JAI PRAKASH YADAV
Digitally signed by JAI PRAKASH YADAV
DN: cn=JAI PRAKASH YADAV, c=IN, o=Personal
Date: 2026.07.13 18:58:13 +05'30'

per Jai Prakash Yadav
Partner
Membership No.: 066943

UDIN: 26066943HKQJQI6122

Place: Mumbai
Date: July 13, 2026

Aquapharm Chemical Limited (Formerly known as "Advaya Chemical Industries Limited")

Registered Office : 9th&10th Floor, "Amar Synergy", 12B, Sadhu Vaswani Road, Pune 411001, India. CIN : U20299PN2024PLC227198

Statement of Unaudited Standalone Financial Results for the quarter ended 30th June 2026

Website : www.aquapharm-india.com, Phone No. : (+91) 20 6609 0000

(All amounts are in INR Crores, unless otherwise stated)

Particulars	Standalone			
	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited (Refer note 3)	Unaudited	Audited
Revenue from Operations	219.26	175.83	210.38	793.23
Other Income	4.81	4.82	6.10	25.84
Total Income	**224.07**	**180.65**	**216.48**	**819.07**
Expenses				
Cost of raw materials consumed	150.38	93.30	111.27	447.37
Changes in inventories of finished goods and work-in-progress	(28.29)	8.89	19.16	19.52
Employee benefits expense	19.26	16.97	18.57	73.14
Finance costs	24.23	23.98	26.47	102.57
Depreciation and amortisation expense	32.66	32.21	32.13	128.55
Other expenses	45.44	34.54	35.88	152.89
Total Expenses	**243.68**	**209.89**	**243.48**	**924.04**
Profit / (Loss) before tax and exceptional item	**(19.61)**	**(29.24)**	**(27.00)**	**(104.97)**
Exceptional item :				
Impact of new labour codes	-	3.87	-	11.54
Profit / (Loss) before tax	**(19.61)**	**(33.11)**	**(27.00)**	**(116.51)**
Tax expense/(credit)				
Current tax	-	-	-	-
Deferred tax	(4.91)	(8.13)	(6.69)	(28.40)
Tax credit relating to earlier years	-	-	(3.22)	(2.77)
Total tax expense/(credit)	**(4.91)**	**(8.13)**	**(9.91)**	**(31.17)**
Profit / (Loss) after tax	**(14.70)**	**(24.98)**	**(17.09)**	**(85.34)**
Other Comprehensive Income (OCI)				
Items that will not be reclassified to profit or loss				
Remeasurements of post employment defined benefit plans	-	0.47	-	0.34
Income tax relating to items that will not be reclassified to Profit or Loss	-	(0.12)	-	(0.09)
Other Comprehensive Income for the period	**-**	**0.35**	**-**	**0.25**
Total Comprehensive Income / (Loss)	**(14.70)**	**(24.63)**	**(17.09)**	**(85.09)**
Paid-up Equity Share Capital (Face value of INR 10/- each)	2,850.00	2,850.00	2,850.00	2,850.00
Other Equity				(199.15)
Earnings / (Loss) per equity share (EPS) (INR)				
(Nominal value per share INR 10/-)				
Basic and diluted*	(0.05)	(0.09)	(0.06)	(0.30)
(* not annualised except for year end)				

1. Additional information as per Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The Company has issued 55,000 rated, listed, secured, redeemable, non-convertible debentures of face value of INR 1,00,000 each, aggregating to INR 550 crore, subscribed by DBS Bank Limited, (referred to as the "Debentures") in the FY 23-24. 15% of the issue amount i.e. INR 82.50 crores have been repaid on 29th January 2025, 15% of the issue amount i.e. INR 82.50 crores have been repaid on 29th January 2026 and INR 385 crores is outstanding as on 30th June 2026 and accordingly the following disclosures are being made as per Regulation 52(4) and 54(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Particulars	Standalone			
	Quarter ended			Year ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	Unaudited	Audited (Refer note 3)	Unaudited	Audited
Debt Equity Ratio	0.45	0.42	0.41	0.42
Debt Service Coverage Ratio	0.27	0.15	1.21	0.45
Interest Service Coverage Ratio	(0.07)	(0.63)	(0.26)	(0.35)
Net Worth (INR Crore)	2,636.15	2,650.85	2,718.85	2,650.85
Net Profit after tax (INR Crore)	(14.70)	(24.98)	(17.09)	(85.34)
Earnings/(Loss) per share (Basic and Diluted) *	(0.05)	(0.09)	(0.06)	(0.30)
Current Ratio	0.75	0.63	0.78	0.63
Long Term Debt to Working Capital Ratio	42.11	- **	22.36	-**
Current Liability Ratio	0.47	0.45	0.43	0.45
Total Debts to Total Assets Ratio	0.29	0.28	0.27	0.28
Debtor Turnover-Days	76.21	93.81	75.53	84.33
Inventory Turnover-Days	96.56	63.84	79.65	57.39
Operating Margin (%)	12.06%	9.10%	9.11%	9.45%
Net Profit Margin (%)	(6.70%)	(14.21%)	(8.12%)	(10.76%)

* not annualised except for year end

** net working capital is negative

The debentures subscribed by DBS Bank Limited for INR 550 crore, are secured by way of 1st ranking pari-paasu charge on all movable fixed and current assets, negative lien on immovable properties of the Company, Hypothecation on investments/loans and advances made in foreign subsidiaries by the Company and Non-Disposal Undertaking on equity shares of the foreign subsidiaries to the lenders of the Company to the extent of the security cover of 1x in terms of the Deed of Hypothecation dated 20th March 2025 executed with the debenture trustee.

There is no deviation or variation in the use of proceeds of issue of the Debentures from the objects stated in the Information Memorandum.

The Company does not have any Outstanding redeemable preference shares as on 30th June 2026.
There is no requirement of creation of capital redemption reserve/ debenture redemption reserve as per the Companies Act, 2013.
As on 30th June 2026, the Company had no outstanding listed commercial papers.

Formulas for computation of above ratios are as follows:

Debt Equity Ratio= (Non Current Borrowings + Current Borrowings) / Total Equity

Debt Service Coverage Ratio=(Net profit/(loss) after tax+ Depreciation and amortisation expense + Finance costs excluding interest on lease liabilities+net loss/(gain) on foreign currency transaction+loss/(gain) on disposal of property,plant and equipment) /Debt Service (Interest+ Principal Loan repayment).

Interest Service Coverage Ratio= EBIT (Profit/(loss) Before Tax + Finance Costs)/Finance Costs
(Finance Costs = Interest expenses on debts and borrowings + Other borrowing costs + net loss/(gain) on foreign currency transaction/translation - interest on Lease rent)

Net worth means the aggregate of Equity Share Capital and Other Equity; Other Equity includes retained earnings and foreign currency translation reserve.

Current Ratio = Total Current Assets / Total Current Liabilities

Long term Debt to Working Capital = Non current borrowings including current maturities of long-term debt/ (Current Assets- Current Liabilities excluding current maturities of long term debt)

Bad Debt to Accounts Receivable ratio= Bad Debt (incl Provision for Bad Debts) / Trade Receivables

Current Liabilty Ratio= Total Current Liabilities / Total Liabilities

Total Debts to Total Assets= (Non Current Borrowings+ Current Borrowings) / Total Assets

Debtors Turnover Ratio Days = Sales(Sales of Finished Goods and Traded Goods) / Trade Receivables.

Inventory Turnover= Sales(Sales of Finished Goods and Traded Goods)/ Inventories (Raw Materials + Semi Finished Goods + Finished Goods + Stores and spares parts (including packing material).

Operating Margin (%)= (Operating Profit (Profit/(loss) Before Tax +Depreciation and amortisation expenses+Finance Costs-Payment of Lease Liability+Net loss / (gain) on foreign currency transaction+Loss/ (gain) on disposal of property, plant and equipment - Other Income) / Revenue from Operations.

Net Profit Margin(%) = Net profit/(loss) after tax / Revenue from Operations

Notes to the Unaudited Standalone Financial Results

2 The above unaudited standalone financial results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on 13th July 2026. These unaudited standalone financial results have been subjected to limited review by the statutory auditors of the Company in accordance with Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("the Regulations") and and who have issued an unmodified conclusion on these unaudited standalone financial results.

3 The figures for the quarter ended 31st March, 2026 are the balancing figures in respect of full financial year upto 31st March, 2026 and unaudited published year-to-date figures upto 31st December, 2025 being the date of the end of the third quarter of the financial year which were subject to a limited review.

4 The Company has only one business segment, i.e. chemical and does not operate in any other reportable segment as per Ind AS 108 : Operating segments.

For and on behalf of Board of Directors of Aquapharm Chemical Limited
(Formerly known as "Advaya Chemical Industries Limited")

Ganesh Vishwanathan

Digitally signed by Ganesh Vishwanathan
Date: 2026.07.13 18:30:33 +05'30'

Ganesh Vishwanathan
Whole-time Director and Chief Financial Officer
(DIN: 11259872)

Pune
13th July 2026

S.R. BATLIBOI & CO. LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India
Tel: +91 22 6819 8000

Independent Auditor's Report on book values of the assets and compliance with respect to financial covenants as at June 30, 2026 for submission to Catalyst Trusteeship Limited (the 'Debenture Trustee')

To
The Board of Directors
Aquapharm Chemical Limited (formerly known as "Advaya Chemical Industries Limited")
12-B, Sadhu Vaswani Road,
Pune 411001

1. This Report is issued in accordance with the terms of the service scope letter dated July 09, 2026 and master engagement agreement dated July 11, 2025 with Aquapharm Chemical Limited (Formerly known as "Advaya Chemical Industries Limited") (hereinafter the "Company").

2. We S.R. Batliboi & Co. LLP, Chartered Accountants, are the Statutory Auditors of the Company and have been requested by the Company to examine the accompanying 'Statement showing maintenance of hundred percent or higher Asset Cover as at June 30, 2026, and compliance with all covenants as per the terms of Debenture Trustee Deed for 8.9% rated, listed, secured, redeemable, non-convertible debenture having face value of Rs 1,00,000 each aggregating to Rs. 550 crores, outstanding as on June 30,2026 is Rs. 385 Crores, (referred to as "Debentures")' (hereinafter the "Statement") which has been prepared by the Company from the Board approved unaudited standalone financial results, underlying books of account and other relevant records and documents maintained by the Company as at and for the period ended June 30, 2026 pursuant to the requirements of the Regulation 56(1)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and SEBI Master Circular No. SEBI/HO/DDHS-PoD3/P/CIR/2024/46, dated May 16, 2024 for Debenture Trustees (hereinafter the "SEBI Circular"), and has been initialed by us for identification purposes only.

   This Report is required by the Company for the purpose of submission with Catalyst Trusteeship Limited (hereinafter the "Debenture Trustee") of the Company to ensure compliance with the SEBI Regulations and SEBI Circular in respect of its Debenture subscribed by DBS Bank Limited. The Company has entered into an agreement with the Debenture Trustee(s) vide agreement dated January 20, 2024 which has been amended through amendment deed dated January 27, 2024, March 20, 2025 and March 16, 2026 (Collectively referred to as "Debenture Trust Deed") in respect of such Debentures.

Management's Responsibility

3. The preparation of the Statement is the responsibility of the Management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

4. The Management of the Company is responsible for ensuring that the Company complies with all the relevant requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular including providing all relevant information to the Debenture Trustee.

Auditor's Responsibility

5. It is our responsibility to provide a limited assurance and conclude as to whether the Book values of assets as included in the Column C to J of Annexure 1 of the Statement are in agreement with the books of account underlying the unaudited standalone financial results of the company as at June 30, 2026.

6. We have performed a limited review of the unaudited standalone financial results of the Company for period ended June 30, 2026 prepared by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and issued an unmodified conclusion dated July 13, 2026. Our review of these financial results was conducted in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI").

7. We conducted our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes issued by the ICAI. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.

8. We have complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

9. Our scope of work did not involve us performing audit tests for the purposes of expressing an opinion on the fairness or accuracy of any of the financial information or the financial results of the Company taken as a whole. We have not performed an audit, the objective of which would be the expression of an opinion on the financial results, specified elements, accounts or items thereof, for the purpose of this report. Accordingly, we do not express such opinion.

10. A limited assurance engagement includes performing procedures to obtain sufficient appropriate evidence on the applicable criteria, mentioned in paragraph 5 above. The procedures performed vary in nature and timing from, and are less extent than for, a reasonable assurance. Consequently, the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed. Accordingly, our procedures included the following in relation to the Statement:

    a) Obtained the Board approved unaudited standalone financial results of the Company for the period ended June 30, 2026.

    b) Traced the book value of assets contained in Column C to J in Annexure 1 of the statement with the books of accounts of the Company underlying the unaudited standalone financial results as at June 30, 2026.

    c) Traced and agreed the principal amount and the interest thereon of the Debentures outstanding as on June 30, 2026 to the underlying books of account maintained by the Company as on June 30, 2026.

    d) Obtained a list of financial covenants applicable to aforesaid Debentures. The management has represented and confirmed that the Company as per Schedule V (Clause 2.13) of the Debenture Trust Deed dated January 20, 2024, read with amendment deeds dated January 27, 2024, March 20, 2025 and March 16, 2026,is not required to test financial covenants including Security Cover Ratio on a quarterly basis and the same is required to be tested only on an annual basis (March end of each financial year), as prescribed in the Debenture Trust Deed. We have relied on the same and not performed any independent procedures in this regard.

e) Performed necessary inquiries with the Management and obtained necessary representations.

Conclusion

11. Based on the procedures performed by us, as referred to in paragraph 10 above and according to the information and explanations received and management representations obtained, nothing has come to our attention that causes us to believe that the Book values of assets contained in Column C to J of Annexure 1 of the Statement are not in agreement with the books of account underlying the unaudited standalone financial results of the company as at June 30, 2026.

Restriction on Use

12. The Report has been issued at the request of the Company, solely in connection with the purpose mentioned in paragraph 2 above and to be submitted with the accompanying Statement to the Debenture Trustee and is not to be used or referred to for any other person. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come. We have no responsibility to update this Report for events and circumstances occurring after the date of this report.

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm Registration Number: 301003E/E300005

JAI PRAKASH YADAV
Digitally signed by JAI PRAKASH YADAV
DN: cn=JAI PRAKASH YADAV, c=IN, o=Personal
Date: 2026.07.13 18:59:37 +05'30'

per Jai Prakash Yadav
Partner
Membership Number:066943

UDIN: 26066943KSKRCA3850

Place of Signature: Mumbai
Date: July 13, 2026

Statement showing maintenance of hundred percent or higher Asset Cover as at June 30, 2026, and compliance with all covenants as per the terms of Debenture Trustee Deed for 8.9% rated, listed, secured, redeemable, non-convertible debenture having face value of Rs 1,00,000 each aggregating to Rs. 550 crores, outstanding as on June 30,2026 is Rs. 385 Crores as per requirement of Regulation 56 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated May 16, 2024 for Debenture Trustees (hereinafter the "SEBI Regulations and SEBI Circular")

1. The Company has the following outstanding listed debentures as at June 30, 2026:
   - 55,000 rated, listed, secured, redeemable, non-convertible debentures of face value of INR 1,00,000 each, aggregating to INR 550 crores at a coupon of 8.90% p.a. subscribed by DBS Bank Limited.
   - Out of the above, 15% of the issue amount i.e. INR 82.50 crores have been repaid on January 29, 2025 and 15% of the issue amount i.e. Rs.82.50 crores have been repaid on January 29, 2026 and balance Rs.385.00 crores is outstanding as on June 30, 2026.

2. Asset Cover with respect to such debentures as computed in Annexure - 1 as at June 30, 2026 is 3.72. Not required to test financial covenants on a quarterly / half yearly basis and the same is required to be tested only on annual basis (March end of financial year), as prescribed in the Debenture Trust Deed. The Company had complied with the security coverage ratio for the financial year 2025-26 as prescribed in the Debenture Trust Deed.

3. The Company is in compliance with all the following applicable covenants as per the Trust Deed dated January 20, 2024 which has been amended through amendment deed dated January 27, 2024, March 20, 2025 and March 16, 2026 (collectively referred to as "Debenture Trust Deed"):

   i. Consolidated Gross Debt/ EBIDTA: Testing of financial covenant relating to 'Consolidated Gross Debt/EBITDA' has been deferred to financial year 2026-27 and thereafter on an annual basis. The Company had complied with the security coverage ratio for the financial year 2025-26 as prescribed in the Debenture Trust Deed.

   ii. Proceeds from non-convertible debenture are used as stated in the Trust Deed

   iii. Maintenance of proper books of accounts to accurately reflect its financial condition

   iv. Payment of all the applicable taxes and stamp duty have been made.

   v. Credit rating by the Rating agency to be reviewed on an annual basis.

   vi. Maintenance of property (including its property and assets forming part of the Security) in good working order and habitable condition and adequately insured

   vii. Necessary compliance in accordance with Schedule III (Part B: Clause 6) of Trust Deed dated January 20, 2024, i.e. effective after the merger date.

   viii. No amendments in the constitutional documents which is likely to adversely impact the debt servicing ability in relation to the Secured Obligations.

   ix. No further loan or facility from any person and/or stand surety or guarantor for any third party obligation and/or provide any loan or advance to any third party

   x. No restricted payments have been made in breach of financial covenants

   xi. No change in control

(We hereby confirm that the Company has complied with all applicable covenants (including financial, affirmative, informative and negative covenants as at June 30, 2026.)

For Aquapharm Chemical Limited (Formerly known as "Advaya Chemical Industries Limited")

Ganesh Vishwanathan

Digitally signed by Ganesh Vishwanathan
Date: 2026.07.13 18:30:52 +05'30'

Authorised Signatory
Dated : July 13, 2026

Aquapharm Chemical Limited (Formerly known as "Advaya Chemical Industries Limited")

Certificate on Security Coverage as on 30th June, 2026

(Amount in INR Crores)

Column A	Column B	Column C [i]	Column D[ii]	Column E[iii]	Column F[iv]	Column G[v]	Column H[vi]	Column I[vii]	Column J	Column J[vii]					Column P	Column Q
Particulars	Description of asset for which this certificate relate (plz add line item, if required)	Exclusive Charge	Exclusive Charge	Pari-Passu Charge	Pari-Passu Charge	Pari-Passu Charge	Assets not offered as Security	Elimination (amount in negative)	(Total C to I)	Related to only those items covered by this certificate					Total Figure as per Balance Sheet	Difference
		Debt for which this certificate being issued	Other Secured Debt	Debt for which this certificate being issued	Assets shared by pari-passu debt holder (includes Debt for which this certificate is issued & Other debt with pari passu charge)	Other assets on which there is pari-passu charge (excluding items covered in column "F")				Market Value for Assets charged on exclusive basis	Carrying/book value for exclusive charge assets where market value is not ascertainable or applicable. (Eg Bank balance, DSRA etc)	Market Value for Pari Passu Charge Assets	Carrying/book value for parri passu charge assets where market value is not ascertainable or applicable. (Eg Bank balance, DSRA etc)	Total Value = (K+L+M +N)		
		Book Value	Book Value	Yes/ No	Book Value	Book Value						Related to Column F			Book value	
ASSETS				No												
Property, Plant and Equipment		-	-		414.90	-	217.70		632.60	-	-	-	632.60	632.60	632.60	-
Capital Work-in-Progress		-	-		12.44	-			12.44	-	-	-	12.44	12.44	12.44	-
Right of Use Assets		-	-		-	-	55.60		55.60	-	-	-	55.60	55.60	55.60	-
Goodwill		-	-		606.57	-			606.57	-	-	-	606.57	606.57	606.57	-
Intangible Assets		-	-		1,957.00	-			1,957.00	-	-	-	1,957.00	1,957.00	1,957.00	-
Intangible Assets under Development		-	-		-	-			-	-	-	-	-	-	-	-
Investments	Equity shares	-	-		281.90	-	-		281.90	-	-	8.00	273.90	281.90	281.90	-
Loans		-	-		8.35	-			8.35	-	-	-	8.35	8.35	8.35	-
Inventories		-	-		232.66	-			232.66	-	-	-	232.66	232.66	232.66	-
Trade Receivables		-	-		183.62	-	-		183.62	-	-	-	183.62	183.62	183.62	-
Cash and Cash Equivalents		-	-		16.43	-	-		16.43	-	-	16.43	-	16.43	16.43	-
Bank Balances other than Cash and Cash Equivalents		-	-		1.32	-	-		1.32	-	-	1.32	-	1.32	1.32	-
Others		-	-		83.47	-	38.80		122.27	-	-	-	122.27	122.27	122.27	-
Total		**-**	**-**		**3,798.66**	**-**	**312.10**	**-**	**4,110.76**	**-**	**-**	**25.75**	**4,085.01**	**4,110.76**	**4,110.76**	**-**
LIABILITIES																
Debt Securities to which this certificate pertains		-			401.05	-			401.05						401.05	-
Other debt sharing pari-passu charge with above debt					203.13				203.13						203.13	-
Other Debt									-						-	-
Subordinated debt									-						-	-
Borrowings									-						-	-
Bank - borrowings			-		386.06	-			386.06						386.06	-
Debt Securities			-		-				-						-	-
Others - borrowings			-		-	-	225.96		225.96						225.96	-
Trade payables			-		-	-	117.52		117.52						117.52	-
Lease Liabilities			-		-	-	0.27		0.27						0.27	-
Provisions			-		-	-	18.77		18.77						18.77	-
Total Equity			-		-	-	2,636.15		2,636.15						2,636.15	-
Others		-	-		-	-	121.85		121.85						121.85	-
Total		**-**	**-**		**990.24**	**-**	**3,120.52**	**-**	**4,110.76**						**4,110.76**	**-**

Computation of Security Cover *	**Amount in INR Crores**
Assets of Aquapharm Chemical Limited (Formerly known as Advaya Chemical Industries Limited) against which security is created	
Property, Plant & Equipment (excluding immovable properties)	414.90
Capital work-in-progress	12.44
Intangible Assets	1,957.00
Goodwill	606.57
Investments	281.90
Loans	8.35
Inventories	232.66
Trade Receivables	183.62
Cash & Cash Equivalents	16.43
Other Bank Balances	1.32
Other Financial Assets	26.86
Other current & non-current assets	56.61
Total assets against which security is created	**3,798.66**
Non-Convertible Debentures raised by Aquapharm Chemical Limited with 1x cover	385.00
Term Loan raised by Aquapharm Chemical Limited with 1x cover	468.13
Other Term Loan raised by Aquapharm Chemical Limited with 1.25x fixed asset coverage ratio having security against all movable net fixed asset + intangible assets excluding current assets of the company	151.33
Interest accrued but not due on Debentures and Other secured debt, as mentioned above	16.05
	1,020.51
Security Cover for Aquapharm Chemical Limited - times	**3.72**
** Requirement as per Debenture Trust Deed of not less than 1 time of the security cover.*	

Ganesh Vishwanathan

Digitally signed by Ganesh Vishwanathan
Date: 2026.07.13 18:31:10 +05'30'